Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:DRUG

Bright Minds Biosciences (DRUG) Stock Price, News & Analysis

→ This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad)
Free DRUG Stock Alerts
$1.13
+0.03 (+2.73%)
(As of 08:36 AM ET)
Compare
Today's Range
$1.13
▼
$1.13
50-Day Range
$0.99
▼
$1.53
52-Week Range
$0.93
▼
$6.44
Volume
553 shs
Average Volume
26,022 shs
Market Capitalization
$5.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media
DRUG stock logo

About Bright Minds Biosciences Stock (NASDAQ:DRUG)

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

DRUG Stock Price History

DRUG Stock News Headlines

January 12, 2024 | msn.com
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
December 6, 2023 | finance.yahoo.com
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management
November 12, 2023 | msn.com
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
November 12, 2023 | finance.yahoo.com
Bright Minds Biosciences Inc. (DRUG.CN)
October 25, 2023 | benzinga.com
Bright Minds Biosciences Stock (NASDAQ:DRUG) Dividends: History, Yield and Dates
August 18, 2023 | seekingalpha.com
DRUG Bright Minds Biosciences Inc.
August 8, 2023 | msn.com
Bright Minds stock rallies ahead of conference call to discuss Phase 1 data
August 8, 2023 | finance.yahoo.com
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
August 7, 2023 | msn.com
Bright Minds reports results from trial to treat refractory epilepsies
July 24, 2023 | benzinga.com
Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials
July 20, 2023 | finance.yahoo.com
Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
July 12, 2023 | benzinga.com
Bright Minds Biosciences Stock (NASDAQ:DRUG), Short Interest Report
July 11, 2023 | msn.com
Bright Minds Goes For 5:1 Shares Consolidation, Hopes To Regain NASDAQ Compliance
July 11, 2023 | finanznachrichten.de
Bright Minds Biosciences: Bright Minds Announces Effective Date of Share Consolidation
June 22, 2023 | finanznachrichten.de
Bright Minds Biosciences: Bright Minds Announces Proposed Share Consolidation
June 22, 2023 | finance.yahoo.com
Bright Minds Announces Proposed Share Consolidation
May 16, 2023 | benzinga.com
Bright Minds Biosciences Stock (NASDAQ:DRUG), Earnings Estimates, EPS, and Revenue
April 20, 2023 | benzinga.com
Bright Minds Biosciences Stock (NASDAQ:DRUG), Analyst Ratings, Price Targets, Predictions
April 19, 2023 | benzinga.com
Bright Minds Biosciences Stock (NASDAQ:DRUG), Trade Ideas
April 19, 2023 | finance.yahoo.com
Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202
April 10, 2023 | finance.yahoo.com
Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research
February 27, 2023 | finance.yahoo.com
Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
February 8, 2023 | finance.yahoo.com
Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements
January 27, 2023 | finance.yahoo.com
Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
December 2, 2022 | finance.yahoo.com
Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement
See More Headlines

Company Calendar

Today
5/20/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
9/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DRUG
CUSIP
N/A
CIK
1827401
Web
brightmindsbio.com
Phone
64-7407-2515
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,470,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-77.40%
Return on Assets
-70.90%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.01
Quick Ratio
8.01

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.30 per share
Price / Book
0.87

Miscellaneous

Outstanding Shares
4,430,000
Free Float
2,542,000
Market Cap
$5.01 million
Optionable
Not Optionable
Beta
1.45

Key Executives

  • Mr. Ian McDonald (Age 35)
    Co-Founder, CEO, President & Director
  • Mr. Ryan E. S. K. Cheung B.Com. (Age 46)
    CA, CPA, Chief Financial Officer
    Comp: $87.44k
  • Dr. Jan Torleif Pedersen M.Sc. (Age 59)
    Ph.D., Chief Science Officer & Director
    Comp: $177.46k
  • Dr. Mark A. Smith M.D. (Age 69)
    Ph.D., Chief Medical Officer
    Comp: $238.66k
  • Dr. Emer Leahy M.B.A. (Age 57)
    Ph.D., Consultant

Key Competitors

View All Competitors

DRUG Stock Analysis - Frequently Asked Questions

How have DRUG shares performed in 2024?

Bright Minds Biosciences' stock was trading at $1.43 at the beginning of the year. Since then, DRUG shares have decreased by 23.1% and is now trading at $1.10.
View the best growth stocks for 2024 here.

When is Bright Minds Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our DRUG earnings forecast.

When did Bright Minds Biosciences' stock split?

Shares of Bright Minds Biosciences reverse split on the morning of Friday, July 14th 2023. The 1-5 reverse split was announced on Friday, July 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

How do I buy shares of Bright Minds Biosciences?

Shares of DRUG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DRUG) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
Urgent Nvidia Warning
Altimetry
Does this make you sick?
Allegiance Gold
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
Global crypto currency reset (41 major banks signed up)
Stansberry Research
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing